Mycophenolate mofetil as a treatment for urticarial dermatitis

Australas J Dermatol. 2014 Nov;55(4):275-8. doi: 10.1111/ajd.12192. Epub 2014 Sep 1.

Abstract

We report two cases of adults with urticarial dermatitis who could not be managed by a variety of treatments but who obtained good control with mycophenolate mofetil (MMF). A clinical response was seen 6-8 weeks from treatment onset and they were maintained on MMF 1 g twice daily (case 1), and MMF 1 g omni mane and 500 mg omni nocte (case 2), with no major exacerbations for many years. MMF is an immunosuppressive agent, which is currently used off-label for many dermatological conditions. To date, there have been no studies investigating the use of MMF as a treatment for urticarial dermatitis. The cases we present suggest that MMF is an effective treatment for this condition, and we recommend that MMF be considered as a treatment option.

Keywords: dermatitis with an urticarial component; mycophenolate mofetil; urticarial dermatitis.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Chronic Disease
  • Dermatitis, Irritant / drug therapy*
  • Dermatitis, Irritant / radiotherapy
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Middle Aged
  • Mycophenolic Acid / analogs & derivatives*
  • Mycophenolic Acid / therapeutic use
  • Retreatment
  • Ultraviolet Therapy
  • Urticaria / drug therapy*
  • Urticaria / radiotherapy

Substances

  • Adrenal Cortex Hormones
  • Immunosuppressive Agents
  • Mycophenolic Acid